[HTML][HTML] Combined anti‐CD20 and mTOR inhibition with factor VIII for immune tolerance induction in hemophilia A patients with refractory inhibitors
BS Doshi, LJ Raffini, LA George - Journal of Thrombosis and Haemostasis, 2020 - Elsevier
Abstract Background Hemophilia A (HA) inhibitor patients that fail traditional immune
tolerance induction (ITI) have increased morbidity and mortality. Preclinical studies support
factor VIII (FVIII) tolerance induction with a combined approach of anti‐CD20 mediated
transient B cell depletion and rapamycin mediated regulatory T cell (Treg) induction.
Methods Two refractory HA inhibitor patients were treated with rituximab, rapamycin, and
FVIII ITI. Their clinical course, anti‐FVIII immunoglobulins, cytokines, and select lymphocytes …
tolerance induction (ITI) have increased morbidity and mortality. Preclinical studies support
factor VIII (FVIII) tolerance induction with a combined approach of anti‐CD20 mediated
transient B cell depletion and rapamycin mediated regulatory T cell (Treg) induction.
Methods Two refractory HA inhibitor patients were treated with rituximab, rapamycin, and
FVIII ITI. Their clinical course, anti‐FVIII immunoglobulins, cytokines, and select lymphocytes …